TY - JOUR
T1 - Smoking enhances the expression of angiotensin-converting enzyme 2 involved in the efficiency of severe acute respiratory syndrome coronavirus 2 infection
AU - Suzuki, Rigel
AU - Ono, Yuki
AU - Noshita, Koji
AU - Kim, Kwang Su
AU - Ito, Hayato
AU - Morioka, Yuhei
AU - Tamura, Tomokazu
AU - Okuzaki, Daisuke
AU - Tagawa, Tetsuzo
AU - Takenaka, Tomoyoshi
AU - Yoshizumi, Tomoharu
AU - Shimamura, Teppei
AU - Iwami, Shingo
AU - Fukuhara, Takasuke
N1 - Funding Information:
We thank H. Kubo and K. Tsushima for their secretarial work; W. Noguchi, K. Oyama, N. Tachibana, T. Matuoka, and M. Honmura for their technical assistance. We also thank Edanz ( https://jp.edanz.com/ac ) for editing a draft of this manuscript. This work was supported by the Ministry of Health, Labour and Welfare of Japan and the Japan Agency for Medical Research and Development (JP21fk018471h0001, JP20fk0108451h0001, JP21nf0101627h0002, JP21fk0108617h0001, JP20fk0108401h0001, and JP21wm0325004h0002 to T.F.), the Japan Society for the Promotion of Science KAKENHI (JP21H02736 to T.F. and JP20K22951, JP21K15452 to R.S.), JST MIRAI Program (JPMJMI20G6 to K.N.), and Moonshot R&D (JPMJMS2021 to S.I. and JPMJMS2025 to S.I.).
Publisher Copyright:
© 2022 The Societies and John Wiley & Sons Australia, Ltd.
PY - 2022
Y1 - 2022
N2 - Smoking is one of the risk factors most closely related to the severity of coronavirus disease 2019 (COVID-19). However, the relationship between smoking history and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity is unknown. In this study, we evaluated the ACE2 expression level in the lungs of current smokers, ex-smokers, and nonsmokers. The ACE2 expression level of ex-smokers who smoked cigarettes until recently (cessation period shorter than 6 months) was higher than that of nonsmokers and ex-smokers with a long history of nonsmoking (cessation period longer than 6 months). We also showed that the efficiency of SARS-CoV-2 infection was enhanced in a manner dependent on the angiotensin-converting enzyme 2 (ACE2) expression level. Using RNA-seq analysis on the lungs of smokers, we identified that the expression of inflammatory signaling genes was correlated with ACE2 expression. Notably, with increasing duration of smoking cessation among ex-smokers, not only ACE2 expression level but also the expression levels of inflammatory signaling genes decreased. These results indicated that smoking enhances the expression levels of ACE2 and inflammatory signaling genes. Our data suggest that the efficiency of SARS-CoV-2 infection is enhanced by smoking-mediated upregulation of ACE2 expression level.
AB - Smoking is one of the risk factors most closely related to the severity of coronavirus disease 2019 (COVID-19). However, the relationship between smoking history and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity is unknown. In this study, we evaluated the ACE2 expression level in the lungs of current smokers, ex-smokers, and nonsmokers. The ACE2 expression level of ex-smokers who smoked cigarettes until recently (cessation period shorter than 6 months) was higher than that of nonsmokers and ex-smokers with a long history of nonsmoking (cessation period longer than 6 months). We also showed that the efficiency of SARS-CoV-2 infection was enhanced in a manner dependent on the angiotensin-converting enzyme 2 (ACE2) expression level. Using RNA-seq analysis on the lungs of smokers, we identified that the expression of inflammatory signaling genes was correlated with ACE2 expression. Notably, with increasing duration of smoking cessation among ex-smokers, not only ACE2 expression level but also the expression levels of inflammatory signaling genes decreased. These results indicated that smoking enhances the expression levels of ACE2 and inflammatory signaling genes. Our data suggest that the efficiency of SARS-CoV-2 infection is enhanced by smoking-mediated upregulation of ACE2 expression level.
UR - http://www.scopus.com/inward/record.url?scp=85141371450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141371450&partnerID=8YFLogxK
U2 - 10.1111/1348-0421.13034
DO - 10.1111/1348-0421.13034
M3 - Article
C2 - 36258658
AN - SCOPUS:85141371450
JO - Microbiology and Immunology
JF - Microbiology and Immunology
SN - 0385-5600
ER -